References
- Paolino G, Didona D, Magliulo G, Iannella G, Didona B, Mercuri SR, et al. Paraneoplastic emphigus: insight into the autoimmune pathogenesis, clinical features and therapy. Int J Mol Sci. 2017; 18(12): 2532. DOI: 10.3390/ijms18122532
- Anhalt GJ. Paraneoplastic pemphigus. J Investig Dermatol Symp Proc. 2004; 9(1): 29–33. DOI: 10.1111/j.1087-0024.2004.00832.x
- Zimmermann J, Bahmer F, Rose C, Zillikens D, Schmidt E. Clinical and immunopathological spectrum of paraneoplastic pemphigus. J Dtsch Dermatol Ges. 2010; 8(8): 598–606. DOI: 10.1111/j.1610-0387.2010.07380.x
- Miyashiro D, Sanches JA. Paraneoplastic skin disorders: a review. G Ital Dermatol Venereol. 2016; 151(1): 55–76.
- Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990; 323(25): 1729–35. DOI: 10.1056/NEJM199012203232503
- Joly P, Richard C, Gilbert D, Courville P, Chosidow O, Roujeau JC, et al. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol. 2000; 43(4): 619–26. DOI: 10.1067/mjd.2000.107488
- Frew JW, Murrell DF. Paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome): clinical presentations and pathogenesis. Dermatol Clin. 2011; 29(3): 419–25, viii. DOI: 10.1016/j.det.2011.03.018
- Kim JH, Kim SC. Paraneoplastic pemphigus: paraneoplastic autoimmune disease of the skin and mucosa. Front Immunol. 2019; 10: 1259. DOI: 10.3389/fimmu.2019.01259
- Amber KT, Valdebran M, Grando SA. Paraneoplastic autoimmune multiorgan syndrome (PAMS): Beyond the single phenotype of paraneoplastic pemphigus. Autoimmun Rev. 2018; 17(10): 1002–1010. DOI: 10.1016/j.autrev.2018.04.008
- Nanda M, Nanda A, Al-Sabah H, Dvorak R, Alsaleh QA. Paraneoplastic pemphigus in association with B-cell lymphocytic leukemia and hepatitis C: favorable response to intravenous immunoglobulins and prednisolone. Int J Dermatol. 2007; 46(7): 767–9. DOI: 10.1111/j.1365-4632.2007.03225.x
- Izaki S, Yoshizawa Y, Kitamura K, Kato H, Hashimoto H, Korman NJ, et al. Paraneoplastic pemphigus: potential therapeutic effect of plasmapheresis. Br J Dermatol. 1996; 134(5): 987–9. DOI: 10.1111/j.1365-2133.1996.tb06349.x
- Lee A, Sandhu S, Imlay-Gillespie L, Mulligan S, Shumack S. Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia. Australas J Dermatol. 2017; 58(4): e240–e242. DOI: 10.1111/ajd.12615
- Ito Y, Makita S, Maeshima AM, Hatta S, Suzuki T, Yuda S, et al. Paraneoplastic pemphigus associated with b-cell chronic lymphocytic leukemia treated with ibrutinib and rituximab. Intern Med. 2018; 57(16): 2395–2398. DOI: 10.2169/internalmedicine.0578-17
- Vezzoli P, Berti E, Marzano AV. Rationale and efficacy for the use of rituximab in paraneoplastic pemphigus. Expert Rev Clin Immunol. 2008; 4(3): 351–63. DOI: 10.1586/1744666X.4.3.351
- Bech R, Baumgartner-Nielsen J, Peterslund NA, Steiniche T, Deleuran M, d’Amore F. Alemtuzumab is effective against severe chronic lymphocytic leukaemia-associated paraneoplastic pemphigus. Br J Dermatol. 2013; 169(2): 469–72. DOI: 10.1111/bjd.12324
- Gu L, Ye S. Tocilizumab cannot prevent the development of bronchiolitis obliterans in patients with castleman disease-associated paraneoplastic pemphigus. J Clin Rheumatol. 2019; 25(5): e77–e78. DOI: 10.1097/RHU.0000000000000675
- Lee J, Bloom R, Amber KT. A systematic review of patients with mucocutaneous and respiratory complications in paraneoplastic autoimmune multiorgan syndrome: Castleman's disease is the predominant malignancy. Lung. 2015; 193(4): 593–6. DOI: 10.1007/s00408-015-9732-8